



Schelin Catheter® beneficial together with TURP

A newly published prospective randomized study[1] from Sahlgrenska Academy, University of Gothenburg, Sweden, shows that it is beneficial to administer intraprostatic injections of mepivacaine/adrenaline with Schelin Catheter in immediate connection with TURP, in terms of blood loss per resected gram.

During a transurethral resection of the prostate (TURP), the most established surgical treatment of symptoms due to benign prostatic hyperplasia, the prostate can bleed profusely, bringing about anemia and compromised oxygen delivery to the entire body.

The primary purpose of the newly published study from Fredrik Stenmark and co-workers was to assess the efficacy of mepivacaine and adrenaline, injected into the prostate using Schelin Catheter, on bleeding. The so-called primary endpoint was to measure blood loss per resected weight of prostate tissue. The study, which was both randomized and controlled, evaluated 81 patients randomly assigned to standard TURP or TURP by intraprostatic injections using Schelin Catheter. The authors conclude that it is beneficial to administer intraprostatic injections of mepivacaine/adrenaline in immediate conjunction with TURP, in terms of blood loss per resected gram. They also believe that the positive results of the study, along with the low frequency of complications, further underscore the importance of their report.

Johan Wennerholm, CEO ProstaLund: "It is very gratifying that the previous hypothesis, that Schelin Catheter can be used to administer adrenaline to the prostate in order to reduce one of the biggest problems with TURP, is now confirmed in this way. Considering that TURP is by far the most common surgical method worldwide, the potential for Schelin Catheter is enormous. Virtually the entire world's urologists is served by our tool."

[1] <https://doi.org/10.2340/sju.v58.7798>

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
05 September 2023 10:00:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Schelin Catheter® beneficial together with TURP